Shingles vaccination: background and advice for community nurses

Area of Science:

• Immunology
• Virology
• Public Health

Background:

• Shingles (zoster) is a reactivation of the varicella-zoster virus (VZV), which also causes chickenpox.
• While chickenpox is typically mild in childhood, VZV reactivation (shingles) can lead to significant morbidity and mortality, particularly in the elderly.
• Post-herpetic neuralgia is a major complication of shingles.

Purpose of the Study:

• To highlight the importance of the Zostavax vaccine in preventing shingles.
• To inform healthcare professionals about UK vaccination guidelines for shingles.
• To encourage proactive promotion of the VZV vaccine among eligible populations.

Main Methods:

• Review of VZV infection, shingles complications, and vaccine availability.
• Analysis of UK vaccination guidelines for Zostavax.
• Emphasis on the role of healthcare professionals in vaccine promotion.

Main Results:

• An effective live-attenuated VZV vaccine, Zostavax, is available.
• UK guidelines recommend Zostavax for individuals aged 70 and 79.
• Vaccination is crucial for preventing shingles and its complications, especially in older adults.

Conclusions:

• Proactive promotion of the Zostavax vaccine by healthcare professionals is essential.
• Eligible individuals (aged 70 and 79 in the UK) should be informed to make educated decisions about VZV vaccination.
• Vaccination is a key strategy to mitigate the public health impact of shingles and post-herpetic neuralgia.